TRDA
Entrada Therapeutics·NASDAQ
--
--(--)
--
--(--)
6.81 / 10
Outperform
Sentiment is positive (6.81/10) and fund‑flow scores 7.85, indicating strong inflows across all investor sizes. Two analysts issued Strong Buy ratings, yet the stock fell 5.99% and weighted expectations diverge from price trend, creating mixed outlook.
Fund Flow Rating
Analyst RatingStrong Buy
Wall Street Opinions
Strong Buy
Strong Buy
100%
Buy
0%
Hold
0%
Sell
0%
Strong Sell
0%
Date2026-02-11
InstitutionGuggenheim
Times predicted1
Historical Win Rate100.0%
What is the analyst consensus for TRDA?
- TRDA holds a Bullish analyst rating, with 100% of experts assigning a Strong Buy grade. Factoring in net Inflows from order flow data, the comprehensive Sentiment Score stands at 6.81/10 (Outperform).
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
